As more specific mutations in Cav1.2 are being identified in LQT8 patients (and for other genes affecting other arrhythmias; see e.g. a database at http://triad.fsm.it/cardmoc/), a demand for new effective drugs, even acting specifically on distinct mutations is generated12, 13. This evidence concerns the gene CACNA1C and Timothy syndrome.